Emory University Takes Position in Ra Pharmctl Inc (RARX)

Emory University bought a new position in Ra Pharmctl Inc (NASDAQ:RARX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 103,606 shares of the company’s stock, valued at approximately $2,206,000. Ra Pharmctl accounts for approximately 2.1% of Emory University’s portfolio, making the stock its 10th largest position. Emory University owned 0.46% of Ra Pharmctl as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. American International Group Inc. bought a new stake in shares of Ra Pharmctl during the first quarter valued at about $102,000. Teachers Advisors LLC acquired a new position in Ra Pharmctl during the fourth quarter valued at $135,000. Wells Fargo & Company MN increased its position in Ra Pharmctl by 151.8% in the first quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after buying an additional 5,700 shares during the period. Fred Alger Management Inc. acquired a new position in Ra Pharmctl during the fourth quarter valued at $223,000. Finally, Norges Bank acquired a new position in Ra Pharmctl during the fourth quarter valued at $304,000. Institutional investors and hedge funds own 62.85% of the company’s stock.

Institutional Ownership by Quarter for Ra Pharmctl (NASDAQ:RARX)

Shares of Ra Pharmctl Inc (RARX) traded down 0.28% during midday trading on Friday, reaching $21.30. The company’s stock had a trading volume of 179,542 shares. The stock has a 50-day moving average price of $23.17 and a 200 day moving average price of $19.70. The stock’s market capitalization is $480.68 million. Ra Pharmctl Inc has a 52 week low of $12.05 and a 52 week high of $27.84.

Ra Pharmctl (NASDAQ:RARX) last announced its earnings results on Thursday, May 11th. The company reported ($0.50) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.08. Equities analysts forecast that Ra Pharmctl Inc will post ($2.08) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Emory University Takes Position in Ra Pharmctl Inc (RARX)” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/06/16/emory-university-invests-2-206-million-in-ra-pharmaceuticals-inc-rarx-updated-updated.html.

Several research firms recently weighed in on RARX. Zacks Investment Research upgraded Ra Pharmctl from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research report on Saturday, May 27th. Jefferies Group LLC restated an “in-line” rating and set a $25.00 price target on shares of Ra Pharmctl in a research note on Tuesday, March 7th. Finally, BMO Capital Markets upped their price target on Ra Pharmctl from $24.00 to $31.00 and gave the stock a “positive” rating in a research note on Tuesday, March 7th. Five research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $27.00.

In other news, major shareholder Bioventures Ltd Novartis sold 12,114 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $22.63, for a total transaction of $274,139.82. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 152,460 shares of company stock worth $3,745,249 over the last ninety days.

Ra Pharmctl Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply